All News

takayasu.jpg

TNF Inhibitors in Takayasu's Arteritis

Jack Cush, MD

A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and  subcutaneous adalimumab in patients with Takayasu arteritis.

Read Article
guidelines.jpg (keep)

Guidance on aromatase inhibitor-associated bone loss with hormone-sensitive breast cancer

EurekAlert!

An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for estrogen-responsive breast cancer, providing practical guidance for both osteoporosis specialists and oncologists.

Read Article
Patient,instruction

The Patient Journey with Rheumatic Disease

Jack Cush, MD

Oton and colleagues have reviewed the "patient journey" - from symptoms to specialty referral in those diagnosed with rheumatic and musculoskeletal diseases (RMDs).

Read Article
Vexas

2025 ACR Guidance on Diagnosis and Management of VEXAS

Jack Cush, MD

The ACR has published a formal international consensus guidance on VEXAS as a resource for clinicians seeking to understand the disease and its management. 

Read Article
RheumNow Podcast square

Repurposing & Pipeline (8.8.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this week’s podcast.

Read Article
Jo1.gottrons.jpg

Dermatomyositis Reviewed

Jack Cush, MD

Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options.

Read Article
JIA.oligoarticular.jpg

Juvenile Idiopathic Arthritis - NEJM Review

Jack Cush, MD

Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM).

Read Article
Giant-Cell_Vasculitis.jpg

2025 BSR Recommendations for ANCA-associated Vasculitis

Jack Cush, MD

The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) have published a guideline for the management of adults with ANCA-associated vasculitis (AAV); specifically three conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA).

Read Article
vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

Rituximab is not Superior in EGPA

Jack Cush, MD

A cohort study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) patients from the French Vasculitis Study Group failed to show superiority of rituximab compared to conventional strategy with glucocorticoids (GS) alone or in combination with cyclophosphamide.

Read Article
RheumNow Podcast square

CKD & Osteoporosis Rx Revisited (7.25.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.

Read Article
Nailfold videocapillaroscopy (NVC) in Dx of systemic sclerosis - study of 258 NVCs found giant capillaries (specificity 98%) & capillary density to be best at defining a scleroderma pattern (39%). Density ≤8 capillaries/mm best defined dropout (AUC 0.911); having both = 91% https://t.co/WQx6fbQiAB
Dr. John Cush RheumNow ( View Tweet)
Retrospective UK study of CPRD dataset (2012-2023) found 22 829 incident CTD Dx (81% F). Over time incidence SLE & Systemic Sclerosis fell, Sjogrens & MCTD stable, & IIM rose 3.23–4.31/100K. IIM had highest mortality (28/1000 py), followed by SSc, SLE, MCTD; lowest SjD (9.7)

Dr. John Cush RheumNow ( View Tweet)

DID YOU KNOW? >30% of Systemic Sclerosis pts present without Raynauds!. Data from 2 large US cohorts, of SSc dx with puffy fingers/hands or other symptoms. Such patients presented with more severe skin and musculoskeletal disease. https://t.co/NP3KeUL5iX https://t.co/XWiAIljujL

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 63 pts w/ Cryoglobulinemia (essential mixed [EM], CTD-related) vasculitis (CryoVas) in remission post RTX induction. W/ 58 mos F/U Relapse rates were 23%, 42%, 71% (@ 1yr, 2yrs, 5yrs). Relapse risk w/ purpura [HR 2.2] & prior CryoVas flare (HR 1.9). https://t.co/6zGgSN8Wfe
Dr. John Cush RheumNow ( View Tweet)
Pipeline of drugs being developed for Scleroderma by these companies - Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Corp., Johnson & Johnson, Prometic, Cytori arGentis - either as fusion proteins, peptides, small molecule, mAb, Polymern& Gene therapy https://t.co/dWRcQ1a3GU
Dr. John Cush RheumNow ( View Tweet)
🧵 Vasculitis is Not One Disease – It’s a Spectrum It’s not a diagnosis. It’s a mechanism. From small-vessel purpura to large-vessel aneurysms, here’s how to recognize and reason through the vasculitis spectrum👇 @Amansharmapgi @DurgaPrasannaM1 @12VRavindran @Kanjivellam https://t.co/eEalTpDTGD

Links:

Aravind Palraj Rheumat_Aravind ( View Tweet)
Emapalumab Approved for MAS in Still’s On June 27th, 2025, the FDA approved emapalumab for macrophage activation syndrome (MAS) in known or suspected Still’s disease (including both adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)) with https://t.co/431PQlzBsV
Dr. John Cush RheumNow ( View Tweet)
Fibrosis in IgG4-related disease due to the overexpression of early growth response-1 (EGR-1) by Epithelial cells that facilitates tissue fibrosis https://t.co/AEaoucfT13 https://t.co/7UVQpkj3cn https://t.co/PuCjh5LQc5

Links:

Dr. John Cush RheumNow ( View Tweet)
Clinical Associations with Anti-RNA Polymerase III Antibodies A systematic review of anti-RNA polymerase III antibodies (ARA) in systemic sclerosis (SSc) patients finds ARA positivity in only 9% of SSc patients, but come with a higher risk of many potentially worrisome https://t.co/p1KVUFPJvN
Dr. John Cush RheumNow ( View Tweet)
US CDC study of age-standardized mortality rate (ASMR) from 1990-2020, there were 39,496 deaths related to scleroderma (SSc) & and 5,163 from SSc w/ renal failure. Deaths lower in males (22%) than females w/ renal failure (78%). Mortality rate of SSc w? renal failure was https://t.co/OT3BHt3E85
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×